Details of an impressive new data collection and cancer care information system is launched and running as expected. This highly technical data system drastically drops the previous amount of search time a cancer specialist has to waste. They are now able to swiftly access loads of patient data, cancer trials and treatment details, new drugs and their uses, research statistics and much more. Everything is available to staff through their computers. Instead of having some of the information, doctors now can find everything out there on cancer and the current proven treatments. This is an exciting time for Cancer Treatment Centers of America. This devoted cancer care place partnered with other healthcare groups Allscripts and Nanthealth to provide this outstanding informational service.
Known for never giving up, Cancer Treatment Centers of America is turning over new rocks to keep finding effective cancer therapies and treatment types. These experts coordinate their information with skilled researchers working tirelessly to find a cancer cure or vaccine. The stakes are high, but CTCA is optimistic above all. They started aggressively treating adult cancers when there were not many treatment options even known. Now, many clinical trials are being done to perfect cancer care and alleviate harsh side effects from any prescribed treatments.
The successes inspire these hard working cancer care specialists to keep on going forward. Each day brings new information. They hope that patients will soon have better treatments to choose, and lower side effects for better health and comfort. During treatment, a full team surrounds the patient with support and guidance. This warm caring endears patients to their staff. Many staff members put in extra time volunteering in cancer care education and funding. They want all cancer patients to get the care that they deserve. The clock is on for a cure.
To Know More Click : http://www.myctca.com
Clay Siegall is the founder and chief executive officer of Seattle Genetics. The Seattle-based biotech company engages in the development of targeted therapy drugs. The corporation zeroes in on the diseases that have not seen considerable mortality improvements for several years. Dr. Siegall holds a B.S. degree in zoology from the prestigious University of Maryland. He also holds a PhD in genetics from the renowned George Washington University.
Since 1998 when the Seattle Genetics was incorporated, Siegall has provided visionary leadership that has helped the company to maintain its authority in the competitive targeted therapy sector. The company developed the first FDA-approved antibody drug conjugate. Moreover, the corporation has a robust pipeline of over 20 drugs and a number of strategic partnerships with Genentech, Bayer, Pfizer and many other drug manufacturers.
Under Siegall’s leadership, Seattle Genetics evolved from a tiny startup with few researchers to a power house in the cancer research industry. Siegall has grand plans for the firm’s future, including the development of different prospective indications and growing list of drugs. Notably, the success of the company is anchored on its research capabilities. Siegall believes that conventional cancer treatment approaches such as systematic chemotherapies will have no place in the future. This is because targeted therapies are more effective and tolerable.
Speaking on how he started in the business, Siegall said that he was always interested in medicine and the power of technology in restoring the health of people. The executive contends that he developed a deep interest in cancer treatment while he was studying zoology at the university.
About Clay Siegall
Clay Siegall is the chairman of the board at Seattle Genetics. The visionary leader has vast experience in developing viable targeted cancer therapies. He has built Seattle Genetics on a strong foundation of drug development practices, rigorous research, scientific innovation, and passion for helping patients.
Siegall has also led the capital raising activities of Seattle Genetics. He has secured more than $675 million for the company through various methods of financing. Before forming the biotech firm, Siegall worked for the National Cancer Institute and the Bristol-Myers Squibb Pharmaceutical Research Institute. Clay has authored more than 70 publications.